British Journal of Haematology

Article	Citations
Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action	347
COVID19 coagulopathy in Caucasian patients	260
Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia	245
Autoimmune haemolytic anaemia associated with COVID‐19 infection	229
Severe COVID‐19 infection and thrombotic microangiopathy: success does not come easily	151
Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis	131
COVID‐19‐associated immune thrombocytopenia	128
Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies	127
Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature	117
COVID‐19 and ABO blood group: another viewpoint	99
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	95
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation	92
SARS‐CoV‐2‐induced remission of Hodgkin lymphoma	90
The association between severe COVID‐19 and low platelet count: evidence from 31 observational studies involving 7613 participants	89
Simultaneous onset of COVID‐19 and autoimmune haemolytic anaemia	89
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐ca	85
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry	83
Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic	82
Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience	81
Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID‐19?	80
Updates on targeted therapies for acute myeloid leukaemia	78
COVID‐19 infection in patients with sickle cell disease	78
Increased CD95 (Fas) and PD‐1 expression in peripheral blood T lymphocytes in COVID‐19 patients	78
Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients	75
Acute aorto‐iliac and mesenteric arterial thromboses as presenting features of COVID‐19	73

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies	72
Disseminated intravascular coagulation: epidemiology, biomarkers, and management	70
Impact of COVID‐19 on red blood cell rheology	69
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination	68
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations	67
Dynamic relationship between D‐dimer and COVID‐19 severity	65
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma	65
Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series	65
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy	64
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity	64
Guidelines on the use of irradiated blood components	62
Machine learning and artificial intelligence in haematology	62
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia	61
Emicizumab treatment and monitoring in a paediatric cohort: real‐world data	61
COVID‐19 infection and sickle cell disease: a UK centre experience	60
More on COVID‐19 coagulopathy in Caucasian patients	57
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐19	57
Prevalence of venous thromboembolism in critically ill patients with COVID‐19	56
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies	55
First COVID‐19 maternal mortality in the UK associated with thrombotic complications	54
Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy	54
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?	54
Delayed‐phase thrombocytopenia in patients with coronavirus disease 2019 (COVID‐19)	51
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic mye	49
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies	48
COVID‐19 mortality in patients on anticoagulants and antiplatelet agents	48
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients	48
Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients	48
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	47
Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B	47
Efficacy of therapeutic plasma exchange in severe COVID‐19 patients	46
Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID‐19	46
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising ant	46
A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience	45
Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold	45
ABO phenotype and death in critically ill patients with COVID‐19	44
Genotype–phenotype correlation in children with hereditary spherocytosis	44
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations	43
MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a pros	43
Early mortality benefit with COVID‐19 convalescent plasma: a matched control study	42
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres	42
COVID‐19 and immunothrombosis: emerging understanding and clinical management	41
Convalescent plasma for persisting COVID‐19 following therapeutic lymphocyte depletion: a report of rapid recovery	41
Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID‐19 pandemic	41
Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID‐19)	41
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study	40
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis	39
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells	39
Haemophagocytic lymphohistiocytosis and Epstein–Barr virus: a complex relationship with diverse origins, expression and outcomes	39
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre	38

A left shift in the oxyhaemoglobin dissociation curve in patients with severe coronavirus disease 2019 (COVID‐19)	38
Evans syndrome in a patient with COVID‐19	38
COVID‐19 in bone marrow transplant recipients: reflecting on a single centre experience	37
Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)	37
Re The source of elevated plasma D‐dimer levels in COVID‐19 infection	37
Secondary HLH is uncommon in severe COVID‐19	37
Terminal complement inhibition dampens the inflammation during COVID‐19	37
Haematological management of major haemorrhage: a British Society for Haematology Guideline	36
Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia	36
Haemoglobin oxygen affinity in patients with severe COVID‐19 infection	35
Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort s	35
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia	35
Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders	35
Incidence and survival of multiple myeloma: a population‐based study of 10 524 patients diagnosed 1982–2017	34
C1 esterase inhibitor and the contact system in COVID‐19	34
Interleukin‐1 blockade with anakinra in acute leukaemia patients with severe COVID‐19 pneumonia appears safe and may result in clinical improvement	34
Anti‐A isohaemagglutinin titres and SARS‐CoV‐2 neutralization: implications for children and convalescent plasma selection	34
The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper	34
Identification of CXCL12‐abundant reticular cells in human adult bone marrow	34
Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis	34
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response	34
Immune thrombocytopenic purpura after SARS‐CoV‐2 vaccine	34
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome	33
Thrombocytopenia as an initial manifestation of COVID‐19; case series and literature review	33
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study	33
Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches	33
Arterial thromboembolic complications in COVID‐19 in low‐risk patients despite prophylaxis	33
Patients with sickle cell disease and suspected COVID‐19 in a paediatric intensive care unit	33
Ruxolitinib for tocilizumab‐refractory severe COVID‐19 infection	32
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion	32
Thrombophilia testing: A British Society for Haematology guideline	32
Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood	32
Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID‐19	32
Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline	32
Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges	32
COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity	31
Relative expansion of CD19‐negative very‐early normal B‐cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR‐T cell therapy: implications for flo	31
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)	31
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries	31
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients	31
Thrombosis in immune thrombocytopenia — current status and future perspectives	31
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy	31
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival	30
Triage tool for the rationing of blood for massively bleeding patients during a severe national blood shortage: guidance from the National Blood Transfusion Committee	30
Eltrombopag added to immunosuppression for children with treatment‐naïve severe aplastic anaemia	30
Application of the LymphGen classification tool to 928 clinically and genetically‐characterised cases of diffuse large B cell lymphoma (DLBCL)	30
p53 is associated with high‐risk and pinpointsTP53missense mutations in mantle cell lymphoma	30
Amelioration of COVID‐19‐related cytokine storm syndrome: parallels to chimeric antigen receptor‐T cell cytokine release syndrome	29
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience	29
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia	29
Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline	29
Reactive lymphocytes in patients with COVID‐19	29
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease	29
Pembrolizumab in relapsed or refractory Richter syndrome	29
Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials	29
SARS‐CoV‐2 infection anxieties and general population restrictions delay diagnosis and treatment of acute haematological malignancies	29
Prevalence and mortality in β‐thalassaemias due to outbreak of novel coronavirus disease (COVID‐19): the nationwide Iranian experience	28
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics	28
Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms	28
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) wi	28
Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation	28
Clinical outcomes of IDH2‐mutated advanced‐phase Ph‐negative myeloproliferative neoplasms treated with enasidenib	28
Temporal changes in immune blood cell parameters in COVID‐19 infection and recovery from severe infection	27
How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future	27
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	27
Atypical lymphocytes in peripheral blood of patients with COVID‐19	27
More on ‘Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia’	27
Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma	27
Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience	27
von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate‐to‐severe COVID‐19 patients	27
New developments in von Willebrand disease	27
Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide	26
Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma	26
FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute pro	26
Are mushroom‐shaped erythrocytes an indicator of COVID‐19?	25
Varying presentations and favourable outcomes of COVID‐19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases	25
Immature platelets as a biomarker for disease severity and mortality in COVID‐19 patients	25
Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma	25
A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation	25
Managing sickle cell patients with COVID‐19 infection: the need to pool our collective experience	25

SARS‐CoV‐2: a new aetiology for atypical lymphocytes	25
Ruxolitinib‐combined doxorubicin‐etoposide‐methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single‐arm, multicentre, phase 2 trial	25
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study	25
Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children	25
Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease	25
Haematological cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date	25
Impact of major bleeding and thrombosis on 180‐day survival in patients with severe COVID‐19 supported with veno‐venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observa	25
Haemophagocytosis in bone marrow aspirates in patients with COVID‐19	25
Abnormal concentration of porphyrins in serum from COVID‐19 patients	24
Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination	24
Effect of low or high doses of low‐molecular‐weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID‐19	24
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open‐label study	24
The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphoma	24
COVID‐19 associated Kikuchi‐Fujimoto disease	24
The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?	23
Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study	23
Absence of hydroxyurea‐induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia	23
Clinical significance of blue‐green neutrophil and monocyte cytoplasmic inclusions in SARS‐CoV‐2 positive critically ill patients	23
Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study	23
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy	23
Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline	22
Adoptive immunotherapy with double‐bright (CD56bright/CD16bright) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof‐of‐concep	22
Vasculo‐toxic and pro‐inflammatory action of unbound haemoglobin, haem and iron in transfusion‐dependent patients with haemolytic anaemias	22
Thrombolysis restores perfusion in COVID‐19 hypoxia	22
Philadelphia‐positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID‐19 pandemic: a Campus ALL study	22
COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience	22
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients	22
Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis	21
Current and future therapies for haemophilia—Beyond factor replacement therapies	21
Second primary malignancy in myelofibrosis patients treated with ruxolitinib	21
Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease	21
Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab	21
Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities	21
Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CB‐TrIP study	21
Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID‐19 pandemic	21
Favourable outcome of coronavirus disease 2019 in a 1‐year‐old girl with acute myeloid leukaemia and severe treatment‐induced immunosuppression	21
Gender‐related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	20
Direct‐acting antiviral agents for hepatitis C virus‐mixed cryoglobulinaemia: dissociated virological and haematological responses	20
Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients	20
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma	20
Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID‐19 infected patients	20
Third dose of COVID‐19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres	20
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy	20
Efficacy and safety of intravitreal methotrexate for vitreo‐retinal lymphoma – 20 years of experience	20
Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura	20
The NICE COVID‐19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact	20
Safety of anti‐SARS‐CoV‐2 vaccination for patients with immune thrombocytopenia	20
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma	20
Interleukin 6‐blockade treatment for severe COVID‐19 in two patients with multiple myeloma	20
Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies	19
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuita	19
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS‐CoV‐2 infection	19
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before	19
The detection of circulating plasma cells may improve the Revised International Staging System (R‐ISS) risk stratification of patients with newly diagnosed multiple myeloma	19
Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study	19
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial	19
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia	19
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*	19
Novel therapies for immune thrombocytopenia	19
Plasma microparticles of intubated COVID‐19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine‐dependent manner	19
Co‐morbidities and mortality associated with transfusion‐dependent beta‐thalassaemia in patients in England: a 10‐year retrospective cohort analysis	19
The role of eosinophil morphology in distinguishing between reactive eosinophilia and eosinophilia as a feature of a myeloid neoplasm	19
Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy	18
Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021	18
Fatigue in children and adolescents with immune thrombocytopenia	18
Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features	18
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report	18
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant	18
Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita	18
Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results	18
Rapid screening of COVID‐19 patients using white blood cell scattergrams, a study on 381 patients	18
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia	18
Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7	18
Haemophilia: factoring in new therapies	18
Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study	18
Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia	18
Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies	18
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent	18
Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials	18
Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses	17
First use of the anti‐VWF nanobody caplacizumab to treat iTTP in pregnancy	17
Clinical and laboratory diagnosis of heritable platelet disorders in adults and children: a British Society for Haematology Guideline	17
Paradoxical effect of SARS‐CoV‐2 infection in patients with immune thrombocytopenia	17
Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study	17
L‐DEP regimen salvage therapy for paediatric patients with refractory Epstein‐Barr virus‐associated haemophagocytic lymphohistiocytosis	17
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia	17
Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico‐biological parameters	17
Complement as the enabler of carfilzomib‐induced thrombotic microangiopathy	17
Donor source and post‐transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency	17
Outcome of early treatment of SARS‐CoV‐2 infection in patients with haematological disorders	17
Combined IL‐6 and JAK/STAT inhibition therapy in COVID‐19‐related sHLH, potential game changer	17
Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study	17
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic	17
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics‐guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with si	17
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	16